Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

LXRX

Lexicon Pharmaceuticals Inc

Sep 06 • 04:00PM ET

1.61

Dollar change -0.01
Percentage change -0.62	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI VXF IWM SCHA IWN VTWO IWO IWC ITOT BBP

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.77	Insider Own	3.45%	Shs Outstand	361.49M	Perf Week	-10.56%
Market Cap	582.00M	Forward P/E	-	EPS next Y	-0.56	Insider Trans	0.00%	Shs Float	349.01M	Perf Month	3.21%
Income	-200.59M	PEG	-	EPS next Q	-0.16	Inst Own	76.85%	Short Float	7.03%	Perf Quarter	-8.00%
Sales	3.64M	P/S	159.89	EPS this Y	14.47%	Inst Trans	11.62%	Short Ratio	8.36	Perf Half Y	-25.12%
Book/sh	0.66	P/B	2.43	EPS next Y	16.92%	ROA	-58.14%	Short Interest	24.53M	Perf Year	-1.23%
Cash/sh	0.86	P/C	1.88	EPS next 5Y	-	ROE	-94.10%	52W Range	0.92 - 3.73	Perf YTD	5.23%
Dividend Est.	-	P/FCF	-	EPS past 5Y	6.80%	ROI	-58.25%	52W High	-56.84%	Beta	1.30
Dividend TTM	-	Quick Ratio	11.49	Sales past 5Y	186.21%	Gross Margin	76.52%	52W Low	75.00%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	11.51	EPS Y/Y TTM	-13.01%	Oper. Margin	-5412.11%	RSI (14)	42.00	Volatility	6.43% 7.32%
Employees	285	Debt/Eq	0.44	Sales Y/Y TTM	792.40%	Profit Margin	-5509.34%	Recom	1.67	Target Price	6.20
Option/Short	Yes / Yes	LT Debt/Eq	0.43	EPS Q/Q	21.61%	Payout	-	Rel Volume	1.18	Prev Close	1.62
Sales Surprise	-52.06%	EPS Surprise	3.95%	Sales Q/Q	419.56%	Earnings	Aug 01 AMC	Avg Volume	2.93M	Price	1.61
SMA20	-5.52%	SMA50	-11.97%	SMA200	-12.04%	Trades		Volume	3,454,840	Change	-0.62%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-17-24	Initiated	H.C. Wainwright	Buy	$10
Apr-30-24	Initiated	Leerink Partners	Outperform	$5
Mar-07-23	Initiated	Jefferies	Hold	$3
Aug-12-22	Initiated	Piper Sandler	Overweight	$10
Jan-29-21	Upgrade	JP Morgan	Underweight → Neutral	$7
Jan-29-21	Downgrade	Wedbush	Outperform → Neutral	$2 → $8
Dec-08-20	Upgrade	Citigroup	Neutral → Buy
Nov-18-20	Upgrade	Gabelli & Co	Hold → Buy
Dec-11-19	Downgrade	Gabelli & Co	Buy → Hold
Nov-08-19	Downgrade	Citigroup	Buy → Neutral	$3 → $4
Sep-11-19	Upgrade	Gabelli & Co	Hold → Buy	$3
Jul-29-19	Downgrade	Stifel	Buy → Hold	$10 → $4
Mar-25-19	Upgrade	Gabelli & Co	Sell → Hold
Jul-31-18	Reiterated	Stifel	Buy	$24 → $23
Feb-23-18	Downgrade	Needham	Buy → Hold
Feb-14-18	Downgrade	JP Morgan	Neutral → Underweight	$10
Mar-01-17	Reiterated	Wedbush	Outperform	$33 → $38
Mar-01-17	Reiterated	H.C. Wainwright	Buy	$26 → $27
Oct-07-16	Initiated	H.C. Wainwright	Buy	$26
Aug-05-16	Reiterated	Wedbush	Outperform	$30 → $31

Show Previous Ratings

Sep-03-24 04:00PM	Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences (GlobeNewswire) -6.94%
08:00AM	New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration (GlobeNewswire)
Sep-01-24 10:26PM	Lexicon Pharmaceuticals, Inc. (LXRX): The Best Multibagger Penny Stock of 2025? (Insider Monkey)
Aug-29-24 08:41PM	10 Best Multibagger Penny Stocks of 2025 (Insider Monkey)
Aug-22-24 11:26AM	Lexicon (LXRX) Up as FDA Maintains Action Date for Zynquista (Zacks)
10:33AM	Loading…
10:33AM	Lexicon to face FDA AdComm for Zynquista approval in diabetes and CKD (Pharmaceutical Technology)
Aug-21-24 08:00AM	Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista (GlobeNewswire) +13.69%
Aug-14-24 12:33PM	Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up (Zacks) -5.20%
Aug-13-24 08:30AM	Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio (GlobeNewswire) +8.81%
07:00AM	Lilly opens R&D hub; Ovid and Lexicon lay off staff (BioPharma Dive)
Aug-07-24 08:00AM	Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists (GlobeNewswire)
Aug-01-24 05:15PM	Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks) -10.22% -16.09%
04:12PM	Lexicon: Q2 Earnings Snapshot (Associated Press Finance)
04:00PM	Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-25-24 08:00AM	Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024 (GlobeNewswire) +7.37%
11:15AM	Loading…
Jul-17-24 11:15AM	FDA Accepts Lexicon's (LXRX) NDA for Type I Diabetes Drug (Zacks)
Jul-16-24 08:00AM	Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission (GlobeNewswire) +5.19%
Jul-15-24 08:00AM	New Published Data Highlights Potential Cost-Savings of INPEFA (sotagliflozin) for Heart Failure (GlobeNewswire) +7.07%
Jul-08-24 09:15AM	Lexicon Board of Directors Appoints Mike Exton, Ph.D. as New Chief Executive Officer and Director (GlobeNewswire)
Jun-21-24 08:00AM	Lexicon Pharmaceuticals Resubmits Sotagliflozin NDA for Type 1 Diabetes (GlobeNewswire) +5.71%
Jun-19-24 08:00AM	Data From Lexicon's RELIEF-DPN 1 Phase 2 Study of LX9211 Published Today in Diabetes Care, a Peer-Reviewed Journal of the American Diabetes Association (GlobeNewswire)
Jun-18-24 08:00AM	Analysis of INPEFA (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology (GlobeNewswire)
Jun-14-24 08:00AM	Findings on the Burdens of Diabetic Peripheral Neuropathic Pain (DPNP) Among Three Lexicon-Sponsored Presentations at the 84th Scientific Sessions of the American Diabetes Association (GlobeNewswire)
May-30-24 04:45AM	Lexicon selects Medidata to advance Phase IIb non-opioid pain drug trial (Clinical Trials Arena)
May-29-24 07:30AM	Lexicon Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2024 (GlobeNewswire)
May-14-24 08:03AM	Lexicon Pharmaceuticals Says Post Hoc Analysis of Infepa Trial Showed Decreased Heart Failure Risk; Shares Gain Pre-Bell (MT Newswires)
07:00AM	New Post-Hoc Analysis of Pooled Phase 3 Data Shows That INPEFA (Sotagliflozin) Reduced Risk of Heart Failure Events in Patients With Preserved Ejection Fraction (GlobeNewswire)
May-09-24 07:30AM	Lexicon Pharmaceuticals to Participate in the Bank of America Securities Healthcare Conference 2024 (GlobeNewswire) +6.78%
May-06-24 10:05AM	Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q1 2024 Earnings Call Transcript (Insider Monkey) +5.17%
May-03-24 07:46AM	Q1 2024 Lexicon Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
04:07AM	Loading…
04:07AM	Lexicon Pharmaceuticals Inc (LXRX) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-02-24 08:59PM	LXRX Stock Earnings: Lexicon Pharmaceuticals Meets EPS, Misses Revenue for Q1 2024 (InvestorPlace)
06:05PM	Lexicon Pharmaceuticals (LXRX) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:03PM	Lexicon Pharmaceuticals Reports Q1 2024 Earnings: Aligns with EPS Projections Amidst Strategic ... (GuruFocus.com)
05:00PM	Lexicon: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-29-24 10:42AM	Lexicon Pharmaceuticals' Chief Executive Lonnel Coats to Retire (MT Newswires)
09:00AM	Lonnel Coats Retires as Chief Executive Officer and Board Member of Lexicon Pharmaceuticals (GlobeNewswire)
07:00AM	Lexicon Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 2, 2024 (GlobeNewswire)
Apr-18-24 08:00AM	Lexicon Pharmaceuticals to Host 2024 Investor Day (GlobeNewswire)
Apr-16-24 12:00PM	All You Need to Know About Lexicon (LXRX) Rating Upgrade to Buy (Zacks) -9.36%
Apr-03-24 08:00AM	Lexicon Pharmaceuticals to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -7.69%
Mar-25-24 09:20AM	Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo (GlobeNewswire) -6.19%
Mar-13-24 12:45PM	Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin (Zacks)
Mar-12-24 08:00AM	New Post Hoc Analysis of inTandem3 Study Demonstrates Improvements In Glycemic Control With Sotagliflozin Treatment in Patients With Type 1 Diabetes and Chronic Kidney Disease (GlobeNewswire) -10.32%
Mar-11-24 08:25AM	Lexicon Pharmaceuticals (LXRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +29.49%
07:34AM	Lexicon: Q4 Earnings Snapshot (Associated Press Finance)
07:15AM	Lexicon Pharmaceuticals Reports Fourth Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
07:05AM	Lexicon Announces Oversubscribed $250 Million Private Placement of Equity Securities (GlobeNewswire)
07:00AM	Lexicon Preparing to Resubmit Sotagliflozin NDA for Type 1 Diabetes Following Feedback From FDA (GlobeNewswire)
Feb-29-24 10:00AM	Analysts Estimate Lexicon Pharmaceuticals (LXRX) to Report a Decline in Earnings: What to Look Out for (Zacks)
Feb-22-24 12:58PM	15 Hot Penny Stocks On the Move (Insider Monkey) -5.58%
Jan-31-24 05:06AM	3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street Analysts (Motley Fool) +6.25%
Jan-23-24 05:21AM	3 of the Fastest-Growing Stocks on the Planet in 2024 (Motley Fool) +15.94%
Jan-08-24 07:00AM	Lexicon Pharmaceuticals Provides Business and Pipeline Update at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-26-23 05:06AM	3 Growth Stocks Expected to Skyrocket in 2024, According to Wall Street (Motley Fool) +7.63%
Dec-21-23 04:15PM	Lexicon Pharmaceuticals To Participate In The 42nd Annual JPMorgan Healthcare Conference (GlobeNewswire)
Nov-30-23 07:30AM	Lexicon Enrolls First Patient in Phase 2b Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) (GlobeNewswire)
Nov-22-23 07:30AM	Lexicon Pharmaceuticals to Participate in the 35th Annual Piper Sandler Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-15-23 01:03AM	Director Philippe Amouyal's Strategic 200,000 Share Purchase in Lexicon Pharmaceuticals Inc (GuruFocus.com)
Nov-12-23 02:10PM	INPEFA (sotagliflozin) Use Associated With Early Clinical Benefit in Heart Failure and Atherosclerotic Events in Analysis of Clinical Data (GlobeNewswire)
Nov-10-23 04:01PM	Lexicon Pharmaceuticals to Participate in the Jefferies London Healthcare Conference (GlobeNewswire) +5.94%
10:53AM	Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-08-23 09:45PM	Q3 2023 Lexicon Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -8.80% -9.21%
07:19AM	Lexicon: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Lexicon Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-03-23 09:00AM	Lexicon Pharmaceuticals to Host Third Quarter 2023 Financial Results Conference Call and Webcast on November 8, 2023 (GlobeNewswire) +5.71%
Nov-02-23 09:00AM	Data on Early Clinical Benefit for INPEFA (Sotagliflozin) Will Be Among Five Lexicon-Sponsored Presentations at the American Heart Association Scientific Sessions 2023 (GlobeNewswire)
Nov-01-23 09:00AM	INPEFA (Sotagliflozin) Receives Coverage From Express Scripts on Its Basic and High Performance Formularies for Commercially Insured Patients (GlobeNewswire) +8.06%
Oct-31-23 04:01PM	Lexicon Strengthens Management Team With Two New Executives (GlobeNewswire)
Oct-30-23 04:01PM	New Data Relating to Sotagliflozin to be Presented at the American Society of Nephrology (ASN) Kidney Week 2023 Annual Meeting (GlobeNewswire) +8.11%
Oct-25-23 08:45AM	Global Diabetes Care Market Size Expected To Reach $41.71 Billion By 2027 (PR Newswire)
Oct-17-23 04:01PM	Data From Two Studies Demonstrating Positive Financial Impact of INPEFA (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting (GlobeNewswire) -8.09%
01:35PM	Hedge Fund and Insider Trading News: John Paulson, Ray Dalio, Starboard Value, Trian Fund Management, ExodusPoint Capital Management, JAT Capital, Lexicon Pharmaceuticals, Inc. (LXRX), Omnicom Group Inc. (OMC), and More (Insider Monkey)
Oct-13-23 11:38AM	Hedge Fund and Insider Trading News: Leon Cooperman, Ray Dalio, Bill Ackman, John Paulson, Altana Wealth Ltd., Apple Inc. (AAPL), Lexicon Pharmaceuticals Inc (LXRX), and More (Insider Monkey) +14.42%
Oct-11-23 11:13AM	Lexicon's (LXRX) Inpefa Gets Preferred Status at Express Scripts (Zacks)
09:00AM	Data Demonstrating Financial Impact of INPEFA (Sotagliflozin) to be Presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023 National Meeting (GlobeNewswire)
Oct-10-23 11:25AM	Why Shares of Lexicon Pharmaceuticals Are Up Tuesday (Motley Fool) +12.00%
09:44AM	Midday movers: PepsiCo, Unity, Rivian Automotive and more (Investing.com)
03:33AM	Lexicon Pharma shares rise after Inpefa gets preferred status at Express Scripts (Investing.com)
Oct-09-23 04:01PM	INPEFA (Sotagliflozin) Receives Preferred Formulary Status With Express Scripts For Medicare Patients (GlobeNewswire) -7.41%
08:00AM	Tom Garner Joins Lexicon as Senior Vice President and Chief Commercial Officer (GlobeNewswire)
Sep-28-23 09:00AM	Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023 (GlobeNewswire) -9.09%
Sep-26-23 09:00AM	Lexicon to Present Study Results Relating to Sotagliflozin and LX9211 at the 59th Annual Meeting of the European Association for the Study of Diabetes (EASD) (GlobeNewswire) +10.38%
Sep-20-23 12:28PM	15 Best Affordable Stocks To Buy Under $5 (Insider Monkey)
Sep-14-23 09:40PM	Insider Buying: Jeffrey Wade Acquires 10,000 Shares of Lexicon Pharmaceuticals Inc (LXRX) (GuruFocus.com)
Sep-07-23 04:30PM	Lexicon Pharmaceuticals to Participate in the H.C. Wainwright & Co. 25th Annual Global Investment Conference (GlobeNewswire)
09:00AM	Lexicon Announces Series of Presentations Relating to LX9211, Its Investigational Drug for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP) (GlobeNewswire)
Aug-21-23 09:00AM	Lexicon to Present Analyses of INPEFA (sotagliflozin) Clinical Study Results and Changing Patterns of Heart Failure Diagnoses at the European Society of Cardiology (ESC) Congress 2023 (GlobeNewswire)
Aug-17-23 09:56AM	10 Healthcare Stocks with Insider Buying (Insider Monkey)
Aug-08-23 09:00AM	Published Analysis of Sotagliflozin (INPEFA(TM)) Clinical Data Demonstrates Significant Reductions in the Risk of Hospital Readmissions for Heart Failure (GlobeNewswire) +7.06%
Aug-04-23 09:12AM	Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) stock most popular amongst private equity firms who own 49%, while individual investors hold 25% (Simply Wall St.)
Aug-03-23 05:15PM	Lexicon Pharmaceuticals (LXRX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:10PM	Lexicon: Q2 Earnings Snapshot (AP Finance)
04:01PM	Lexicon Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-28-23 04:01PM	Lexicon Pharmaceuticals to Host Second Quarter 2023 Financial Results Conference Call and Webcast on August 3, 2023 (GlobeNewswire)
08:00AM	Lexicon Elects Diane E. Sullivan to Board of Directors (GlobeNewswire)
Jun-30-23 06:52AM	Daily Vickers Top Buyers & Sellers for 06/30/2023 (Argus Research) +5.53%
Jun-27-23 06:46AM	Daily Vickers Top Buyers & Sellers for 06/27/2023 (Argus Research)
Jun-23-23 08:45PM	Lexicon Announces Planned Advancement of LX9211 Into Late-Stage Development (GlobeNewswire) -8.44%

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
COATS LONNEL	Former Affiliate	Aug 15 '24	Proposed Sale	1.60	300,000	480,000		Aug 15 04:47 PM
Swain Judith L	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	48,364	Apr 29 04:21 PM
SOBECKI CHRISTOPHER J	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	167,055	Apr 29 04:20 PM
LEFKOWITZ ROBERT J MD	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	48,364	Apr 29 04:18 PM
DEBBANE RAYMOND	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	1,348,879	Apr 29 04:17 PM
BARKER SAM L	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	87,649	Apr 29 04:17 PM
Amouyal Philippe	Director	Apr 28 '24	Option Exercise	0.00	8,032	0	248,364	Apr 29 04:16 PM
COATS LONNEL	Chief Executive Officer	Nov 16 '23	Buy	1.05	90,000	94,797	914,359	Nov 17 04:55 PM
COATS LONNEL	Chief Executive Officer	Nov 10 '23	Buy	1.01	10,000	10,100	824,359	Nov 13 05:31 PM
DEBBANE RAYMOND	Director	Oct 10 '23	Buy	1.14	508,306	579,367	849,153	Oct 12 04:01 PM
DEBBANE RAYMOND	Director	Oct 11 '23	Buy	1.08	342,874	370,784	1,192,027	Oct 12 04:01 PM
DEBBANE RAYMOND	Director	Oct 12 '23	Buy	1.03	148,820	153,805	1,340,847	Oct 12 04:01 PM
WADE JEFFREY L	President and CFO	Sep 14 '23	Buy	1.38	10,000	13,800	264,341	Sep 14 05:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LXRX

Lexicon Pharmaceuticals Inc

Upgrade your FINVIZ experience